Q32 Bio Q3 2026 net loss widens 20% to $8.9 million year over year
QTTB•Q32 Bio’s third-quarter 2026 net loss widened 20% year over year to $8.9 million. It had $289.6 million in cash and cash equivalents at September 30, which it expects to fund operations through planned Phase 3 topline results.
1. Quarterly results and programs
Research and development expenses rose 42% to $5.1 million, while general and administrative expenses climbed 38% to $5.5 million. Q32 Bio expects to begin a registration-directed bempikibart program for severe or very severe alopecia areata in the first half of 2027, subject to regulatory discussions. In SIGNAL-AA’s 16-week off-drug follow-up, bempikibart responses were maintained or deepened, supporting the potential for less frequent maintenance dosing.
